Sickle Cell Anemia Testing and Screening Market Overview

The global sickle cell anemia testing and screening market size is poised for significant growth, with the market size expected to increase from USD 1.7 billion in 2025 to approximately USD 3.6 billion by 2033, expanding at a robust CAGR of 9.8% during the forecast period. This market encompasses a range of testing methods, including hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), point-of-care tests, and genetic testing, each playing a vital role in early detection and management of sickle cell anemia, a genetic blood disorder characterized by abnormal hemoglobin production.

The growth of the global sickle cell anemia testing and screening market is mainly driven by the increasing number of cases worldwide. This is especially true in regions like sub-Saharan Africa, India, the Middle East, and parts of North America. Awareness campaigns from health groups and governments have increased demand for newborn screening and diagnostic tests. Advances in molecular diagnostics and quick testing devices are also helping expand the market by making tests easier, more reliable, and cheaper. The analysis shows a clear move toward using genetic testing and better chromatography methods in both public and private health care. Partnerships between the government and private companies, along with more funding for genetic studies and population screening, are helping the market grow. Modern labs with automation and better infrastructure are making screening faster and more efficient. This improves the speed of diagnosis and makes it easier to start treatment early.

Sickle Cell Anemia Testing and Screening Market Drivers and Opportunities

The rising global prevalence and burden of sickle cell disease are anticipated to lift the sickle cell anemia testing and screening market during the forecast period

The global market for sickle cell anemia testing and screening is growing quickly, mainly because the disease is becoming more common worldwide. Sickle cell anemia (SCA) is one of the most common inherited blood disorders, impacting millions of people across the globe. It is especially prevalent in sub-Saharan Africa, India, the Middle East, and parts of South America. The World Health Organization reports that over 300,000 babies are born each year with serious hemoglobin disorders like sickle cell disease. This number is expected to rise as populations grow in areas at high risk. The increasing number of cases pushes health systems to set up strong early detection programs. Governments and health groups face growing pressure to expand screening efforts, particularly for newborns and those most at risk. Detecting the disease early is essential because it allows for quick medical help, lowers infant death rates, and greatly improves patients’ quality of life. The rising costs of treating advanced stages of sickle cell disease add to the need for better testing options. As a result, there is a growing demand for affordable and easy-to-use screening tools. This has led to the creation and use of new diagnostic methods like point-of-care tests, HPLC, and DNA tests. All this drives the market forward.

Advancements in diagnostic technology and accessibility drive the global sickle cell anemia testing and screening market

Technological innovation is transforming the landscape of sickle cell anemia testing by making diagnostics faster, more accurate, and increasingly accessible. Traditional methods like hemoglobin electrophoresis and HPLC have been refined for greater efficiency, while newer modalities such as molecular testing and next-generation sequencing (NGS) have expanded diagnostic capabilities. Genetic testing, in particular, is gaining traction due to its ability to detect carriers and confirm diagnoses in prenatal and early-life stages. Point-of-care (POC) testing devices have also emerged as a game changer, especially in low-resource settings, by enabling decentralized testing with minimal infrastructure and training. These advancements are reducing the turnaround time for results and supporting early intervention strategies. Companies are also investing in miniaturized and portable diagnostic platforms that combine digital integration and AI-based result interpretation, making them ideal for remote or rural deployment. Furthermore, cloud-based data management platforms are improving how patient data is stored, tracked, and analyzed, aiding in longitudinal disease management and research. Diagnostic manufacturers are collaborating with public health agencies and NGOs to distribute low-cost, high-accuracy kits globally. With increasing emphasis on personalized healthcare and preventive diagnostics, these technological strides are significantly expanding the market potential, improving patient outcomes, and driving the adoption of sickle cell testing across both developed and emerging economies.

Opportunity for the Sickle Cell Anemia Testing and Screening Market

The growing role of public-private partnerships and global health initiatives is a significant opportunity in the global sickle cell anemia testing and screening market

Public-private partnerships (PPPs) and international health organizations are opening new doors for market growth. These groups play a key role in launching large testing programs, especially in areas with limited resources. Private firms can supply new diagnostic tools, provide training, and handle logistics. Public agencies contribute funding, policies, and healthcare infrastructure. Many governments are working with diagnostic companies, drug makers, and nonprofits to improve access to testing and include it in national health plans. Projects supported by the Global Alliance for Sickle Cell Disease, WHO-led pilots, and the Gates Foundation are driving policy changes and boosting funding efforts. These programs help expand the market and increase demand for test kits, reagents, and screening services. They also encourage local manufacturing, build capacity, and cut down reliance on imports. This partnership can speed up innovation to better fit regional healthcare needs. As more countries adopt preventive care and universal health coverage, cooperation between private companies and public health agencies will be essential. Together, they will help grow testing programs and support long-term market progress.

Sickle Cell Anemia Testing and Screening Market Scope

Sickle Cell Anemia Testing and Screening Market Report Segmentation Analysis

The global Sickle Cell Anemia Testing and Screening Market industry analysis is segmented by testing method, by age group, by sector, and by region.

The Hemoglobin Electrophoresis segment accounted for the largest market share in the global Sickle Cell Anemia Testing and Screening market

By Testing Method, the market is segmented into Hemoglobin Electrophoresis, High-Performance Liquid Chromatography (HPLC), Point-of-Care Tests, Genetic Testing, and Others. The Hemoglobin Electrophoresis segment holds the largest share of the global sickle cell testing market, making up 43.2%. Its popularity comes from being a trusted, affordable, and precise method to detect abnormal hemoglobin linked to sickle cell disease. It is still considered the gold standard in many clinics, especially government and university labs. Hemoglobin electrophoresis separates different types of hemoglobin clearly, helping doctors identify and classify sickle cell traits early. This method is a favorite choice for newborn screening and in areas with strong lab systems. Its hold on the market is expected to continue due to high demand in locations where sickle cell is common and because it is part of public health screening programs.

The Newborn Screening segment holds a major share in the Sickle Cell Anemia Testing and Screening market

By Age Group, the market is segmented into Newborn Screening, Ages 1 to 25, and Ages 26 and Above. The Newborn Screening segment has the largest share in this market. Detecting sickle cell early in newborns helps start treatment sooner and cuts down on death rates. Growing awareness about the importance of early diagnosis, along with law requirements in countries like the United States, India, and Nigeria, has helped this part grow fast. International health groups are also encouraging large screening programs in places where the disease is widespread. These efforts are likely to keep this segment a major player in market growth, especially as healthcare improves and more countries adopt universal screening plans.

The Government Labs segment dominates in the Sickle Cell Anemia Testing and Screening market

By Sector, the market is segmented into Government Labs, Private Labs, Corporate Labs, and Public-Private Partnerships (PPP). The Government Labs segment leads the global market for sickle cell testing. Public hospitals and government-run labs are the main players in running nationwide screening and awareness drives. These labs often receive funding and support from national health agencies and international groups. They do most of the large-scale testing, especially for newborns and pregnant women. These labs are common in areas with fewer resources. As the focus on early detection and prevention continues, government labs are expected to stay in front. They benefit from policies and continued funding to improve public healthcare services.

The following segments are part of an in-depth analysis of the global Sickle Cell Anemia Testing and Screening Market:

Sickle Cell Anemia Testing and Screening Market Share Analysis by Region

The North America region is projected to hold the largest share of the global Sickle Cell Anemia Testing and Screening market over the forecast period.

In 2025, North America led the global market for sickle cell anemia testing and screening, claiming about 44% of total revenue. This region's strong position is due to its advanced healthcare system, widespread newborn screening programs, and government support for testing for genetic and blood disorders. The United States plays a big role, with all states requiring newborn screening and policies that cover costs. Public awareness campaigns also help keep testing high. North America is quick to adopt new testing methods like high-performance liquid chromatography (HPLC), hemoglobin electrophoresis, and point-of-care tests. These tools improve the speed and accuracy of diagnoses. Collaborative efforts between hospitals, research centers, and agencies like the CDC and NIH boost investment in early screening, genetic counseling, and disease management. The presence of major diagnostic companies and ongoing research keeps North America at the top of the market.

Meanwhile, the Asia Pacific region is expected to grow the fastest in the coming years. Rising cases of the disease, better public health awareness, and more accessible healthcare all contribute to this growth. Countries such as India and Thailand are working harder to set up broad screening programs, especially for newborns and those at high risk. Increased healthcare spending, support from global organizations, and the availability of low-cost testing options are pushing market growth higher across the region.

Sickle Cell Anemia Testing and Screening Market Competition Landscape Analysis

The market is competitive, with several established players and new entrants offering a range of products. Some of the key players are STRECK, INC., Daktari Diagnostics, BIOMEDOMICS INC., Laboratory Corporation of America Holdings, and HEMOTYPE.

Global Sickle Cell Anemia Testing and Screening Market Recent Developments News:

• In October 2024, Bio-Rad Laboratories introduced the Vericheck ddPCR Empty-Full Capsid Kit, leveraging Droplet Digital PCR (ddPCR) technology to assess AAV samples for capsid titer, genome titer, and the proportion of full capsids. This cost-efficient solution delivers highly accurate and repeatable data, enhancing gene therapy development while maintaining regulatory standards.
• In April 2024, Streck unveiled the Protein Plus BCT, an advanced blood collection tube designed to stabilize protein levels in blood samples during storage. This innovation ensures sample integrity for downstream applications like mass spectrometry and immunoassays, offering labs greater logistical flexibility without sacrificing analytical precision.

The Global Sickle Cell Anemia Testing and Screening Market is dominated by a few large companies, such as

●        STRECK, INC

●        Daktari Diagnostics

●        BIOMEDOMICS INC.

●        Laboratory Corporation of America Holdings

●        Request A Test, Ltd

●        HALCYON BIOMEDICAL INCORPORATED

●        Silver Lake Research Corporation

●        HEMOTYPE

●        HEMEX HEALTH

●        Bio-Rad Laboratories, Inc

●        Other Prominent Players